Professional Marketing briefs

Share this article:
Sanofi-Aventis settled a lawsuit accusing the company of underpaying 4,000 female reps in the US, and will pay $15.4 million as part of the settlement. Affected reps will see an increase in their base pay as a result of the settlement. Meanwhile a Novartis rep prevailed in her suit against the company, which she accused of slashing her territory and eliminating her position in retaliation for having taken maternity leave.

Valeant Pharmaceuticals entered into an agreement with Spear Pharmaceuticals for rights to commercialize Refissa, a prescription wrinkle and sun damage cream. Valeant will pay $12 million and the companies will share netprofit.

Arena Pharmaceuticals is looking for a commercial partner for its weight loss drug lorcaserin, pending approval, but will launch without if need be, the company told Reuters. The company is competing with Vivus Inc and Orexigen Therapeutics for first-to-market status.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?